SCHEMBL25191022

SCHEMBL25191022

COc1ccc(/C=C/C(=O)c2ccc(O)cc2)cc1COCC(F)(F)F

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 7/20 0.66
▸ KMT2A Q03164 7/20 0.66
▸ LMNA P02545 4/20 0.66
▸ ALDH1A1 P00352 4/20 0.66
▸ KDM4E B2RXH2 2/20 0.66
▸ CTSL P07711 1/20 0.60
▸ MAPT P10636 5/20 0.58
▸ CXCL12 P48061 2/20 0.56
▸ THRB P10828 1/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ ABCG2 Q9UNQ0 2/20 0.55
▸ CA1 P00915 1/20 0.55
▸ CA2 P00918 1/20 0.55
▸ CAPN1 P07384 1/20 0.52
▸ P4HB P07237 2/20 0.51
▸ CALM1 P0DP23 1/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ CYP1A1 P04798 1/20 0.51
▸ CYP1B1 Q16678 1/20 0.51
▸ F3 P13726 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25195965 0.90 MEN1 (0.62) MEN1KMT2ALMNAALDH1A1KDM4E
SCHEMBL25207219 0.86 MEN1 (0.68) MEN1KMT2ALMNAALDH1A1KDM4E
SCHEMBL30384302 0.86 MEN1 (0.68) MEN1KMT2ALMNAALDH1A1KDM4E
SCHEMBL25194968 0.86 CYP19A1 (0.67) MEN1KMT2ALMNAALDH1A1CTSL
SCHEMBL25191683 0.85 MEN1 (0.72) MEN1KMT2ALMNAALDH1A1KDM4E
SCHEMBL25202126 0.82 MEN1 (0.71) MEN1KMT2ALMNAALDH1A1KDM4E
SCHEMBL25285449 0.82 CTSL (0.67) MEN1KMT2ALMNAALDH1A1KDM4E
SCHEMBL31233221 0.82 CTSL (0.67) MEN1KMT2ALMNAALDH1A1KDM4E
SCHEMBL25198208 0.80 MEN1 (0.76) MEN1KMT2ALMNAALDH1A1KDM4E
SCHEMBL25198797 0.80 MEN1 (0.86) MEN1KMT2ALMNAALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 — — US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 — — US disclosed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 — — WO disclosed
EP-4429763-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS Yewsavin, Inc. (US) 2024-09-18 — — EP disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 — — US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B MEN1 3367/4885KMT2A 2792/4885LMNA 1180/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 MEN1 2457/4885KMT2A 3188/4885LMNA 1817/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 MEN1 2457/4885KMT2A 3188/4885LMNA 1817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback